Pure Global
NCT06218069

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)
Radboud University Medical Center·Phase 2/3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
NSCLC
Drug/Device/Intervention
Sasanlimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Radboud University Medical Center
Location
Tuebingen,Nijmegen, Germany,Netherlands
Timeline & enrollment
Phase
Phase 2/3
Start date
Mar 01, 2024
End date
Mar 01, 2027
Enrollment
20 participants
Primary outcome

Number of participants with successful completion of curative surgery within 42 days after start of subcutaneous sasanlimab as neo-adjuvant treatment.,The number of CTC grade ≥3 toxicity related to subcutaneous sasanlimab as neo-adjuvant treatment.,Detection of treatment induced immune related responses after subcutaneous sasanlimab as neo-adjuvant treatment.

Summary

This study investigates whether a single subcutaneous administration of anti-PD-1 antibody
 can induce CD8+ T-cell tumor-infiltration that can be non-invasively monitored with
 [89Zr]crefmirlimab berdoxam PET imaging as an imaging biomarker.

Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06218069
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06218069 through Pure Global AI's free database. This Phase 2/3 trial is sponsored by Radboud University Medical Center and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.